Each week, our Regional Roundup delivers the most important and timely life sciences news from around the region. From groundbreaking research to fundraising, new development projects, and who’s hiring — we bring you the top stories that matter most. Stay informed with a curated selection of the latest news, delivered directly to your inbox weekly.
The BioHealth Capital Region is rethinking how science moves from discovery to impact. This week, that shift is showing up at nearly every stage. One company has secured $8.3 million in NIAID and FDA contracts to develop research models, while $3 million in federal funding is launching a Baltimore hub dedicated to advancing non-animal drug development tools. Together, those investments point to a growing push for better ways to study disease and evaluate potential therapies before they reach patients.
Further down the pipeline, that progress is already taking shape. IGC Pharma completed enrollment of 168 patients in its Phase 2 CALMA Alzheimer’s trial ahead of a Q4 readout, while QIAGEN expanded its QIAstat-Dx portfolio with an FDA-cleared panel capable of identifying gram-negative bloodstream infections and antibiotic resistance markers in about an hour.
The evolution isn’t stopping at R&D. HHS and EPA are bringing six federal agencies together to strengthen the science behind glyphosate review, while Kymanox is questioning whether continuous manufacturing could eventually challenge the massive stainless-steel bioreactors that have long defined biologics production. From how therapies are studied and tested to how they’re regulated and manufactured, this week’s news shows an ecosystem reconsidering what the next generation of life sciences should look like.
Financial
Tracking the capital moving through the BioHealth Capital Region — funding rounds, M&A activity, and investment trends shaping Maryland, DC, and Virginia’s life sciences companies.
Maryland Stem Cell Research Commission Awards Over $4.8 Million in First FY2027 Funding Cycle
Fifteen investigators across the state received awards spanning early discovery, validation and commercialization, supporting work targeting diseases from Parkinson’s and ALS to leukemia and muscular dystrophy. The latest round also highlights a bigger challenge for the region: demand for funding continues to outpace the resources available. Read More >
$87M Bet on Breaking Cell Therapy’s Cold-Chain Barrier
ARPA-H is putting up to $87 million behind an ambitious effort to rethink how cell therapies are produced, stored and transported. ATCC will play a key role in determining whether the technology delivers. As the program’s independent validator, ATCC will put emerging approaches to the test as researchers work toward a major goal: reducing cell therapy’s dependence on ultra-cold storage. Read More >
$8.3 Million to Advance Next-Generation Research Models
ATCC secured $8.3 million across three new federal contracts from NIAID and the FDA to advance next-generation, human-relevant research models. The awards include $4.2 million to develop a lung-on-a-chip system for influenza research, $2.4 million for a brain and blood-brain barrier model to study neuroinvasive viruses, and $1.7 million to develop pediatric brain tumor organoids for drug evaluation. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
Eric Cantor Named Next President and CEO of PhRMA
Eric Cantor will take control of PhRMA as both CEO and President, bringing decades of experience from covering public policy, healthcare legislation, and business strategy. Cantor succeeds Stephen Ubl and will officially step into the role on November 9. Read More >
Sam Jazzo Joins ARPA-H as a Senior Advisor
Sam Jazzo joins the agency as Senior Advisor after nearly four years at Kaiser Permanente Ventures, bringing experience across digital health, investing and entrepreneurship as ARPA-H works to move some of its most ambitious health innovations closer to real-world impact. Read More >
Maciej Szymaszek Named Head of Commercial AI Strategy at AstraZeneca
Maciej Szymaszek has been promoted to Head of Commercial AI Strategy, Innovation and Business Operations after helping scale AI tools and agentic platforms to more than 45,000 colleagues globally. His expanded role signals what’s next as AstraZeneca looks to turn AI adoption into broader business impact. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across Maryland, DC, and Virginia’s life sciences and biotech employers.
Meet Virginia’s Top Employers for the Next Generation of Life Sciences Talent
Virginia is spotlighting the employers helping turn students into the Commonwealth’s next generation of talent. This year’s Top Employers for Interns include a strong showing from life sciences, biotech and healthcare organizations, recognizing companies and institutions investing in paid, hands-on experiences that connect the classroom to long-term careers in the region. Read More >
From Discovery To Production
More than $15.5 billion in announced investments from AstraZeneca, Eli Lilly and Merck are reshaping the Mid-Atlantic’s life sciences footprint. Across Virginia and Maryland major manufacturing projects are creating demand for thousands of scientists, engineers and skilled workers, signaling the region’s evolution from a research powerhouse into a destination for advanced biopharmaceutical production. Read More >
Who’s hiring?!
Top Employer
With a mission to save and improve lives through leading-edge science, Merck develops medicines and vaccines that address some of the world’s most pressing health challenges. Its teams work across areas including oncology, vaccines, infectious diseases, cardiometabolic disease, immunology, neuroscience, and ophthalmology.
Merck’s team members contribute to research and innovation across every stage of drug development, from discovery to bringing new treatments to patients. With opportunities across Research, Clinical Development, Data Science & AI, Regulatory Affairs, Manufacturing, Quality, and Medical Affairs, Merck offers a wide range of paths for professionals looking to make an impact in life sciences.
They are currently hiring across 20+ roles across the BioHealth Capital Region. Apply Now >
Other employers and available roles we’re paying attention to this week:
- Thermo Fisher Scientific (Richmond, VA) is hiring an Assistant Scientist – Entry Level – Vaccines / Immunochemistry | Apply Now >
- Emmes (Rockville, MD) is hiring a Business Analyst – Essex Management | Apply Now >
- Terumo Medical (Elkton, MD) is hiring a Software Quality Engineer I | Apply Now >
- Westat (Bethesda, MD) is hiring a Biostatistician (Senior Statistical Associate) – Clinical Research | Apply Now >
- LifeSprout (Baltimore, MD) is hiring a Manufacturing Technician | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across the BioHealth Capital Region.
Completed Enrollment in Phase 2 CALMA Alzheimer’s Trial
IGC Pharma completed enrollment in its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s dementia. The trial enrolled 168 participants across the U.S. and Canada, with final dosing expected to conclude in early November. IGC Pharma plans to report topline results in Q4 2026 as it evaluates the therapy’s potential for further clinical and regulatory development.Read More >
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN completed its U.S. QIAstat-Dx bloodstream infection portfolio following FDA clearance of a new panel that can detect 13 gram-negative bacterial pathogens and 18 antibiotic resistance markers in about an hour. Combined with its previously cleared gram-positive and fungal panel, the system can now identify 33 pathogen targets and 28 resistance markers, giving labs faster information to help guide treatment for serious bloodstream infections. Read More >
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08
Cartesian Therapeutics shared new retreatment data for Descartes-08 that adds to the growing evidence behind its approach to treating generalized myasthenia gravis. The latest results point to deep and durable responses in patients receiving additional treatment, offering another look at the therapy’s potential as Cartesian moves toward its next major clinical milestone. Read More >
Ecosystem
The partnerships, programs, and policy moves building the BioHealth Capital Region’s life sciences infrastructure — and the organizations driving it forward.
UMSOP Looks to the Future with Innovation, Discovery, and a Stronger Community at the Center
The University of Maryland School of Pharmacy is looking ahead with a new 2026–2031 strategic plan centered on “pharmapreneurship,” discovery and stronger connections between research and the communities it serves. From plans for a new innovation accelerator to an evolving approach to education and collaboration, Dean Sarah L.J. Michel outlined how UMSOP plans to turn more ideas into real-world impact. Read More >
HHS and EPA Announce New Scientific Partnership
HHS and EPA launched a new scientific partnership to strengthen EPA’s ongoing review of glyphosate. The agencies will form a joint working group spanning six federal agencies to share scientific information, identify research gaps, and expand research into potential human health effects. Read More >
Dulles Takes Virginia’s Pharma Supply Chain Global
Washington Dulles International Airport is getting a bigger seat at the table in global pharmaceutical logistics. Through VEDP’s new strategic membership in Pharma.Aero, Virginia is joining a network of more than 100 life sciences, aviation and supply chain organizations, opening the door to new collaboration while strengthening the Commonwealth’s position as a gateway for pharmaceutical and healthcare products. Read More >
Baltimore Becomes Home to a National Push to Reinvent Drug Development
A $3 million federal investment is putting Baltimore at the center of a national effort to change how new medicines are developed and evaluated. The newly launched National Center to Accelerate Cures will bring together regulatory expertise, infrastructure and industry connections to help promising non-animal research tools move from emerging science toward FDA acceptance and broader use in drug development. Read More >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in DMV biotech and life sciences this week.
NIH launches new PubMed tool to strengthen research replication and reproducibility
NIH launched Linked Discoveries, an experimental PubMed tool designed to help researchers see how an individual scientific finding connects to the larger body of evidence. Instead of treating a paper in isolation, the tool is intended to make it easier to examine whether later research supports, contradicts, or builds on a finding, essentially tackling the reproducibility problem in science. Read More >
Experimental MS Drug Reverses Paralysis, Vision Loss in Lab Model
UVA researchers found that Kamuvudine K-9, a drug derived from HIV medications already approved for use in people, not only stopped disease progression but reversed paralysis and vision loss in a mouse model of multiple sclerosis. That stands out because current MS treatments primarily aim to prevent future inflammatory attacks rather than restore neurological function that has already been lost. Read More >
Stainless-steel bioreactor dinosaurs
Kymanox Executive Advisor Roger Lias explores how continuous manufacturing, smaller footprints and real time analytics are challenging the industry’s traditional approach, and what still needs to change before the next generation of biologics manufacturing can truly take over. Read More >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across the BioHealth Capital Region’s life sciences ecosystem that you don’t want to miss.
Maryland Bionetworking Summit
Thursday, October 8 • 6–8 PM • Rockville, MD
Hosted by UMBC-Shady Grove | Register Now >
Science in the City
Wednesday, October 7 • 4–6 PM • Baltimore, MD
Hosted by UM BioPark | Register Now >
Business of Health Employer Expo 2026
Friday, November 6 • 1–3 PM • Baltimore, MD
Hosted by Johns Hopkins Carey Business School + Johns Hopkins Life Design Lab | Register Now >
Did we miss something!? Drop us a line →
Stay connected to BioHealth Capital Region life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the BioHealth Capital Region Roundup every Friday.
The week’s most important life sciences news from BioHealth Capital Region— delivered to your inbox.
